https://uamc-3203inhibitor.com..../racial-differences-
Probabilistic susceptibility analysis was carried out to asses design robustness. OUTCOMES The progressive costs of epidermis allograft to Mepilex Ag and SSD were $907.71 and $1257.86, respectively. The progressive high quality adjusted life year (QALY) gains from allograft over Mepilex Ag and SSD were 0.011 and 0.016. This yielded an incremental cost-utility ratio for allograft vs. Mepilex Ag of $84,189.29/QALY compared with an incremental cost-utility ratio of $79,684.63/QALY for allograft vs. SSD. Pr
Like
Comment
Share
